pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
insulin · news · pharmadog
← back to insulin
News mentioning insulin
98
stories
5d
Nova Biomedical® Announces Global Medical Device Correction for StatStrip® Glucose Hospital Meter
fda recalls
8d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
10d
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
10d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
11d
STAT+: Overton won’t get a vote before midterms
stat
11d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
11d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
12d
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
12d
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
stat
12d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
12d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
12d
STAT+: It really is bleak out there, and list prices matter
stat
12d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
13d
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
15d
STAT+: Lilly wins approval for once-weekly insulin shot
stat
15d
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
16d
FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with Novo
endpoints
16d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
23d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
24d
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
24d
Sling catches $123M series C for thyroid eye disease pill
biospace
25d
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
fiercebiotech
Sep 10, 26
Encoded raises $275M series F for Dravet syndrome gene therapy
biospace
Sep 9, 26
Kura spins diabetes work into a Lilly-backed biotech startup
biopharma dive
Sep 9, 26
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
Sep 9, 26
Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy
fiercebiotech
Sep 9, 26
Opinion: Autonomous AI will beat AI-assisted physicians at some medical tasks by 2030
stat
Sep 8, 26
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
stat
Sep 4, 26
Menarini signs $771M deal to take Gan & Lee GLP-1 to European market
fiercebiotech
Aug 28, 26
Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
fiercebiotech
← prev
page 1 of 4
next →
